🇺🇸 Peg-Interferon Alpha-2A in United States

12 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Nausea — 2 reports (16.67%)
  2. Thrombocytopenia — 2 reports (16.67%)
  3. Arthralgia — 1 report (8.33%)
  4. Bone Marrow Failure — 1 report (8.33%)
  5. Cerebellar Haemorrhage — 1 report (8.33%)
  6. Cerebellar Infarction — 1 report (8.33%)
  7. Cerebral Ischaemia — 1 report (8.33%)
  8. Cerebrovascular Accident — 1 report (8.33%)
  9. Chest Injury — 1 report (8.33%)
  10. Chest Pain — 1 report (8.33%)

Source database →

Peg-Interferon Alpha-2A in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Peg-Interferon Alpha-2A approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Peg-Interferon Alpha-2A in United States?

Hoffmann-La Roche is the originator. The local marketing authorisation holder may differ — check the official source linked above.